VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
复制标题

VS38C和CD38-MultiePitope抗体可为多发性骨髓瘤患者提供高度可比的最小残留疾病数据。

DOI:
10.1093/ajcp/aqab163
复制
发表时间:
2022-04-01
影响因子:
3.5
通讯作者:
van der Velden VHJ
van der Velden VHJ
中科院分区:
医学4区
文献类型:
--
作者:
Broijl A;de Jong ACM;van Duin M;Sonneveld P;Kühnau J;van der Velden VHJ

文献摘要

参考文献

被引文献

相似文献

比较使用 EuroFlow 方法获得的流式细胞术微小残留病 (MRD) 数据,包括 CD38 多表位 (ME) 抗体或 VS38c 抗体。我们评估了多发性骨髓瘤 (MM) 患者的 29 份骨髓样本,其中 15 人在过去 6 个月内接受过达雷妥尤单抗治疗。我们评估了 MRD 数据和荧光强度。两种方法之间的定性 MRD 数据 100% 一致。在 MRD 阳性样本 (n = 14) 中,MRD 水平显示出极好的相关性 (R2 = 0.999)。尽管正常浆细胞和 MM 细胞中 VS38c 染色均较强,与达雷妥尤单抗治疗无关,但与正常浆细胞相比,MM 细胞中 CD38 的染色强度较低,并且在达雷妥尤单抗治疗的患者中,两种细胞类型上的 CD38 表达均显着降低。 CD38-ME 和 VS38c 都可以在 MM 患者中进行可靠的 MRD 检测,但 VS38c 的高表达可以更容易地识别 MM 细胞,特别是在接受达雷妥尤单抗治疗的患者中。
To compare flow cytometric minimal residual disease (MRD) data obtained using the EuroFlow approach, including the CD38-multiepitope (ME) antibody or the VS38c antibody. We evaluated 29 bone marrow samples from patients with multiple myeloma (MM), of whom 15 had received daratumumab within the past 6 months. We evaluated MRD data and fluorescence intensities. Qualitative MRD data were 100% concordant between the 2 approaches. In MRD-positive samples (n = 14), MRD levels showed an excellent correlation (R2 = 0.999). Whereas VS38c staining was strong in both normal plasma cells and MM cells, independent of daratumumab treatment, staining intensities for CD38 were lower in MM cells compared with normal plasma cells, and on both cell types CD38 expression was significantly reduced in daratumumab-treated patients. Both CD38-ME and VS38c allow reliable MRD detection in MM patients, but the high expression of VS38c allows easier identification of MM cells, especially in daratumumab-treated patients.
DOI: 10.1002/cyto.b.21249
发表时间: 2016-01
期刊: Cytometry. Part B, Clinical cytometry
影响因子: --
作者:
Stetler-Stevenson M;Paiva B;Stoolman L;Lin P;Jorgensen JL;Orfao A;Van Dongen J;Rawstron AC
通讯作者: Rawstron AC
DOI: 10.1093/ajcp/aqz153
发表时间: 2020-02-01
影响因子: 3.5
作者:
Courville, Elizabeth L.;Yohe, Sophia;Linden, Michael A.
通讯作者: Linden, Michael A.
DOI: 10.1038/leu.2012.122
发表时间: 2012-09
期刊: LEUKEMIA
影响因子: 11.4
作者:
Kalina, T.;Flores-Montero, J.;van der Velden, V. H. J.;Martin-Ayuso, M.;Boettcher, S.;Ritgen, M.;Almeida, J.;Lhermitte, L.;Asnafi, V.;Mendonca, A.;de Tute, R.;Cullen, M.;Sedek, L.;Vidriales, M. B.;Perez, J. J.;te Marvelde, J. G.;Mejstrikova, E.;Hrusak, O.;Szczepanski, T.;van Dongen, J. J. M.;Orfao, A.
通讯作者: Orfao, A.
DOI: 10.1016/j.jim.2019.112680
发表时间: 2019-12-01
影响因子: 2.2
作者:
Glier, Hana;Novakova, Michaela;Kalina, Tomas
通讯作者: Kalina, Tomas
DOI: 10.1016/s0140-6736(19)31240-1
发表时间: 2019-07-06
期刊: LANCET
影响因子: 168.9
作者:
Moreau, Philippe;Attal, Michel;Sonneveld, Pieter
通讯作者: Sonneveld, Pieter